Peut-on défendre l’industrie pharmaceutique ? (notice n° 1004654)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02261cam a2200241 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250125134958.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | von der Weid, Guillaume |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Peut-on défendre l’industrie pharmaceutique ? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2018.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 26 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | L’industrie pharmaceutique est victime d’une image détestable dans l’opinion publique. Alors même qu’elle a pour but de soigner, elle est plus déconsidérée encore que les cigarettiers ou l’industrie automobile. Il est nécessaire d’analyser cette situation par trois prismes imbriqués : 1) la complexité d’un marché dont la plupart des coûts sont cachés ; 2) la difficulté d’une société hyperconnectée à organiser des débats sur des questions politiques qui touchent aux valeurs ; 3) et enfin la disjonction qui structure nos mentalités, entre la morale et le profit. C’est à cette condition qu’une industrie aussi critique humainement que porteuse économiquement pourra redevenir un acteur à part entière du monde de la santé, qui puisse participer à l’amélioration de l’offre de santé pour les populations. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | The drug industry has a poor public image. Although its role is to treat disease, it has a poorer reputation than cigarette makers or the automotive industry. This situation must be analysed from three overlapping points of view: 1) the complexity of a market, in which most of the costs are hidden; 2) the difficulty of a connected society to organize debates on political questions related to basic values, and finally 3) the pervading distinction between morality and profits. This clarification might help the industry to become a fully fledged actor in the field of healthcare in order to participate in the improvement of the healthcare offer for the population. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | industrie pharmaceutique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | marchandisation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | coûts et analyse des coûts |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | drug industry |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | commodification |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | costs and cost analysis |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Santé Publique | 30 | 1 | 2018-03-14 | p. 101-103 | 0995-3914 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-sante-publique-2018-1-page-101?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-sante-publique-2018-1-page-101?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux